Pyrimidine Analogues Market
Number of pages: 100 | Report Format: PDF | Published date: May 10, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
8% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Application, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global pyrimidine analogues market is expected to register a revenue CAGR of 8% during the forecast period.
Pyrimidine Analogues Market Fundamentals
Pyrimidine analogues, which are utilized as anticancer medicines, are a broad set of drugs with similar structures but somewhat distinct modes of action, activities, and activity spectra. These substances are nucleoside analogues and are classified as antimetabolites because they interfere with or compete with nucleoside triphosphates in the production of DNA, RNA, or both. The agents are cytosine analogues (azacitidine, decitabine, cytarabine, gemcitabine) or uracil analogues (fluorouracil, floxuridine, capecitabine) with antineoplastic efficacy in cell and animal models. Pyrimidine analogues are a class of anticancer medications with identical structures but somewhat different mechanisms of action, activities, and activity spectra. These nucleoside analogues are antimetabolites because they interfere with or compete with nucleoside triphosphates in the synthesis of DNA, RNA, or both. The drugs have antineoplastic activity in cell and animal models and are cytosine analogues (azacitidine, decitabine, cytarabine, gemcitabine) or uracil analogues (fluorouracil, floxuridine, capecitabine).
The research study on the pyrimidine analogues market overview thoroughly analyzes the market, along with the aspects that either help or hinder the market's growth, such as its drivers, challenges, and opportunities. The research also discusses the list of businesses that operate in this market and their efforts to establish themselves as major players through expansion plans and innovative ideas. It also emphasizes current events that support the market's revenue expansion.
This report is an important tool for the industry stakeholders to gather all the information about the market, customers, and competition. The report also provides the readers with valuable insights on the segmentation, regions, market size & forecast, revenue CAGRs, and other valuable data to help make informed strategic decisions. The study compiles information gathered from industry participants and specialists across the industry value chain. The report also taps into the qualitative and quantitative assessments by industry analysts. Our reports use different methods for estimating the market size and forecast, including secondary research, surveys and interviews, and statistical modeling. With these steps, our reports provide the most accurate market data. These datasets will cumulatively provide in-depth pyrimidine analogues market forecast to the industry stakeholders.
Pyrimidine Analogues Market Dynamics
The global increase in cancer prevalence will be a primary driver of the pyrimidine analogues market's expansion. As per GLOBOCAN 2020, in 2020, that there will be 19.3 million new cases of cancer worldwide (18.1 million excluding non melanoma skin cancer) and over 10 million cancer deaths (9.9 million excluding nonmelanoma skin cancer). With an expected 2.3 million new cases (11.7%), female breast cancer has surpassed lung cancer as the most often diagnosed malignancy. Lung (11.4%), colorectal (10.0%), prostate (7.3%), and stomach (5.6%) cancers are next in line. Other reasons such as changing lifestyle and more awareness will favorably influence the market growth rate corresponding to the growing cancer rates. In addition, developments in medical infrastructure, increased government financing, and rising disposable income levels are factors that will accelerate the growth rate of the pyrimidine analogues market.
Pyrimidine Analogues Market Ecosystem
Pyrimidine Analogues Market, by Type
Pyrimidine Analogues Market, by Application
Pyrimidine Analogues Market by Type
[677856]
Nucleotide synthesis inhibitors segment is likely to grow significantly during forecast periods. The increase in R&D efforts, the introduction of new products, and the emergence of new markets will create advantageous prospects for the pyrimidine analogues market during the projected period. Furthermore, the significant unmet demand for existing cancer treatments, as well as advancements in drug delivery technology, will accelerate market expansion in the future. Based on the applications, lung cancer is the most prominent revenue contributor in the global pyrimidine analogues market. In 2020, with an estimated 1.8 million fatalities (18%), lung cancer remained the most common type of cancer. It was then followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. These figures are indicative of the significant need for a wide range of therapeutic agents for lung cancer management, and hence support the demand for pyrimidine analogues in the lung cancer segment.
Segmentation of the market refers to the division of the industry into subgroups based on factors such as type, application, etc. Market segmentation data helps businesses to understand the preferences and unique needs of different customer groups and develop targeted sales strategies. This information also helps in identifying potential pyrimidine analogues market growth opportunities.
Pyrimidine Analogues Market by Region
The pyrimidine analogs market is projected to remain dominant in North America and Europe. With large increases in government investment on pharmaceutical research, the East and South Asia pyrimidine analogs market is likely to develop at a profitable rate. The United States holds the largest revenue share in the pyrimidine analogues market. This is predominantly attributed to the high cancer burden in the country, better reimbursements for cancer therapies and swift adoption of novel treatments. According to projections from the American Cancer Society, the United States is expected to see 1,918,030 new cancer cases and 609,360 cancer deaths in 2022, with lung cancer being the primary cause of death accounting for about 350 of those fatalities daily.
Based on the regions, the global pyrimidine analogues market is segmented into:
Regional demarcation of the industry will provide information on geographic pockets regarding pyrimidine analogues market outlook, size, share, and growth rate. This data helps businesses evaluate the expansion potential into new regional markets, understand the competitive threats across different regions, and develop localized sales and expansion strategies.
Key Components of the Report
Pyrimidine Analogues Market Competitive Landscape
Some of the prominent market players in the global pyrimidine analogues market include,
The market competitive landscape is performed by collecting and analyzing information about the key competitors, the present industry trends, and market dynamics. It includes information collection and analysis on factors such as products, pricing, geographic outreach, customer demographics, marketing strategies, and recent developments. Competitive landscape assessment will help businesses identify the current prevalent or potential opportunities and threats keeping in mind the pyrimidine analogues industry trends.
Pyrimidine Analogues Market Strategic Developments
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Reasons to Buy this Report
Pyrimidine analogues, utilized as anticancer medicines, are a broad set of drugs with similar structures but somewhat distinct modes of action, activities, and activity spectra. These substances are nucleoside analogues and are classified as antimetabolites because they interfere with or compete with nucleoside triphosphates in the production of DNA, RNA, or both.
The revenue CAGR is the global pyrimidine analogues market expected to be around 8% during the forecast period.
Significant research findings are increasing the uptake of pyrimidine analogues in several therapies.
An increase in R&D efforts and the emergence of new markets are creating new growth opportunities in the global pyrimidine analogues market.
Expansion of the therapeutic base of the existing molecules is a key
The increase in cancer prevalence will be a primary driver of the pyrimidine analogues market growth.
Some of the prominent market players in the global pyrimidine analogues market include Teva Pharmaceutical Industries Ltd., CELON LABS, Eli Lilly & Company, Novartis AF, and Amgen Inc., among others.
Nucleotide Synthesis Inhibitors segment has a significant share in the global pyrimidine analogues market.
*Insights on financial performance are subject to the availability of information in the public domain